Hubei Biocause Heilen Pharmaceutical Co., Ltd. (SHE:301211)

China flag China · Delayed Price · Currency is CNY
9.29
-0.22 (-2.31%)
Jun 11, 2026, 12:44 PM CST
Market Cap3.97B -15.5%
Revenue (ttm)459.02M +8.7%
Net Income33.80M -47.6%
EPS0.08 -45.3%
Shares Out 417.60M
PE Ratio118.88
Forward PEn/a
Dividend0.06 (0.63%)
Ex-Dividend DateJun 12, 2026
Volume1,507,934
Open9.36
Previous Close9.51
Day's Range9.24 - 9.69
52-Week Range9.26 - 16.95
Beta0.52
Analystsn/a
Price Targetn/a
Earnings DateJul 31, 2026

About SHE:301211

Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including non-steroidal anti-inflammatory raw materials ibuprofen and dexibuprofen, cardiovascular raw materials torsemide and milrinone, anti-tumor raw material... [Read more]

Sector Healthcare
Founded 1995
Employees 952
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 301211
Full Company Profile

Financial Performance

In 2025, SHE:301211's revenue was 453.31 million, an increase of 1.67% compared to the previous year's 445.86 million. Earnings were 34.91 million, a decrease of -61.87%.

Financial Statements